CTRI/2012/03/002518已完成2 期
Immunogenicity and Safety of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India
Sanofi Pasteur SA0 个研究点目标入组 189 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 189
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Aged 18 to 45 years on the day of inclusion
- •- Informed consent form has been signed and dated by the subject (and by an independent witness, if applicable)
- •- Subject is able to attend all scheduled visits and to comply with all trial procedures
- •- Subject in good health, based on medical history and physical examination.
排除标准
- •- Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination)
- •- Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination
- •- Planned participation in another clinical trial during the present trial period
- •- Planned receipt of any vaccine in the 4 weeks following any trial vaccination
- •- Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response
- •- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- •- Known seropositivity for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C reported by the subject
- •- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine(s) used in the trial or to a vaccine containing any of the same substances
- •- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- •- Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures
- •- Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
- •- Identified as an Investigator or employee of the Investigator or study center, with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
研究者
相似试验
进行中（未招募）
1 期
A phase IIIb, randomized, multicenter, open-label study in 688 subjects aged from 9 to 60 years in the PhilippinesDengue FeverDengue Hemorrhagic FeverEUCTR2019-003136-23-Outside-EU/EEASanofi Pasteur SA688
进行中（未招募）
1 期
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Given as a Booster Injection in Adolescents and Adults Who Previously Completed the 3-dose Schedule in a Study Conducted in SingaporeDengue FeverDengue Hemorrhagic FeverEUCTR2019-000993-44-Outside-EU/EEASanofi Pasteur SA118
进行中（未招募）
不适用
Study of Sanofi Pasteur's dengue vaccine in Healthy Subjects Aged 2 to 45 Years in Viet NamPrevention of symptomatic dengue diseaseEUCTR2014-001709-41-Outside-EU/EEASanofi Pasteur SA180
进行中（未招募）
不适用
Study of Sanofi Pasteur's dengue vaccine in healthy children aged 2 to 14 Years in Asia to evaluate its efficacyPrevention of symptomatic dengue diseaseEUCTR2014-001708-24-Outside-EU/EEASanofi Pasteur SA10,278
进行中（未招募）
不适用
Study of Sanofi Pasteur's dengue vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America to evaluate its efficacyPrevention of symptomatic dengue diseaseEUCTR2014-001716-19-Outside-EU/EEASanofi Pasteur SA20,875